NO922447L - HYBRID MOLECULE WITH TRANSLOCATION REGION AND CELL BINDING REGION - Google Patents

HYBRID MOLECULE WITH TRANSLOCATION REGION AND CELL BINDING REGION

Info

Publication number
NO922447L
NO922447L NO92922447A NO922447A NO922447L NO 922447 L NO922447 L NO 922447L NO 92922447 A NO92922447 A NO 92922447A NO 922447 A NO922447 A NO 922447A NO 922447 L NO922447 L NO 922447L
Authority
NO
Norway
Prior art keywords
region
hybrid molecule
moiety
cell
hybrid
Prior art date
Application number
NO92922447A
Other languages
Norwegian (no)
Other versions
NO922447D0 (en
Inventor
John R Murphy
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1990/007619 external-priority patent/WO1991009871A1/en
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of NO922447D0 publication Critical patent/NO922447D0/en
Publication of NO922447L publication Critical patent/NO922447L/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Hybridmolekyl som omfatter en første del, en andre del og en tredje del bundet sammen med kovalente bindinger, (a) den første delen omfatter en del av det bindende området til en celle-bindende forbindelse, hvis del er i stand til å binde hybridmolekylet i oppfinnelsen til en dyrecelle; (b) den andre del som omfatter et område av en translokasjonsregion i et protein, hvis del transporterer den tredje delen over cellens cytoplasmamembran; og (c) den tredje delen som omfatter en kjemisk forbindelse som skal innføres.i cellen, forutsatt at (i) hybridmolekylet er fremstilt ved å uttrykke et rekombinant DNA-molekyl som koder for hybridmolekylet, og (ii) den andre og tredje delen er ikke deler av det samme naturlig-forekom- mende polypeptidtoksin; et rekombinant DNA-molekyl som koder for hybridmolekylet; og en fremgangsmåte for fremstilling av hybridmolekylet.A hybrid molecule comprising a first moiety, a second moiety, and a third moiety bonded together with covalent bonds; (a) the first moiety comprises a portion of the binding region of a cell-binding compound whose moiety is capable of binding the hybrid the invention of an animal cell; (b) the second portion comprising a region of a translocation region of a protein whose portion carries the third portion across the cytoplasmic membrane of the cell; and (c) the third part comprising a chemical compound to be introduced into the cell, provided that (i) the hybrid molecule is prepared by expressing a recombinant DNA molecule encoding the hybrid molecule, and (ii) the second and third moieties are not parts of the same naturally occurring polypeptide toxin; a recombinant DNA molecule encoding the hybrid molecule; and a process for preparing the hybrid molecule.

NO92922447A 1989-12-22 1992-06-19 HYBRID MOLECULE WITH TRANSLOCATION REGION AND CELL BINDING REGION NO922447L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45609589A 1989-12-22 1989-12-22
US53827690A 1990-06-14 1990-06-14
PCT/US1990/007619 WO1991009871A1 (en) 1989-12-22 1990-12-21 Hybrid molecules having translocation region and cell-binding region

Publications (2)

Publication Number Publication Date
NO922447D0 NO922447D0 (en) 1992-06-19
NO922447L true NO922447L (en) 1992-08-19

Family

ID=27376503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922447A NO922447L (en) 1989-12-22 1992-06-19 HYBRID MOLECULE WITH TRANSLOCATION REGION AND CELL BINDING REGION

Country Status (1)

Country Link
NO (1) NO922447L (en)

Also Published As

Publication number Publication date
NO922447D0 (en) 1992-06-19

Similar Documents

Publication Publication Date Title
NO2012001I2 (en) Ipilimumab (INN) - Claims In Basic Patent
ES2093623T3 (en) MONOVALENT AND OLIGOVALENT, BIO-SPECIFIC AND OLIGO-SPECIFIC RECEIVERS, THEIR PREPARATION AND USE.
ES557103A0 (en) A PROCEDURE FOR PREPARING A HYBRID PROTEIN
DE3369466D1 (en) Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
EP0434713A4 (en) Hiv-1 envelope muteins lacking hypervariable domains
NO891711L (en) HIV ENV-CODED PEPTIDE AFFECTED FOR AA INJECTION ANTI-INHIBITIVE ANTIBODIES IN MAMMALS.
EP0175360A3 (en) Peptide antibodies and their use in detecting oncogene products
EP0446273A4 (en) Monoclonal antibodies to feline-t-lymphotropic lentivirus
DE69434384D1 (en) METALKOMPLEXBILDNER
SE8204811L (en) DNA FRAGMENT INCLUDING A SIGNAL SEQUENCE
NO922447L (en) HYBRID MOLECULE WITH TRANSLOCATION REGION AND CELL BINDING REGION
FI970428A0 (en) Cells with CD4 lid receptors and corresponding molecules and methods
DK0629238T3 (en) Autotaxin: Motility-stimulating protein useful for cancer diagnosis and therapy
Bidlack et al. Preparation of Fab fragments from a mouse monoclonal IgM
EP0207165A4 (en) Polypeptide secretion-causing vector, microorganisms transformed by said vector, and process for preparing polypeptide using said microorganisms.
NO923415L (en) IMPROVED CHIMER TOXINS
NO882518L (en) PROCEDURES FOR IMPROVED BINDING TO ANTIBODY, ANTIBODY FRAGMENTS, HORMONES AND OTHER BINDING AGENTS, AND CONJUGATES THEREOF.
PT76274A (en) Antibodies and antigens useful in the diagnosis and treatment of cancer